Fexapotide Triflutate (NX-1207)

About Nymox Pharmaceutical

Nymox Pharmaceutical is a decades-old, publicly traded biotech with a mission to revolutionize the treatment of urological disorders, primarily BPH. Its core achievement is the development of fexapotide triflutate, a novel injectable oligopeptide that has completed large Phase 3 trials and demonstrated durable symptom relief and a reduction in surgical interventions in long-term studies. The company's strategy is to advance this single asset through regulatory approval, leveraging a lean, virtual operational model to manage resources while targeting a massive, aging global population in need of better BPH therapies.

About Nymox Pharmaceutical

Nymox Pharmaceutical is a decades-old, publicly traded biotech with a mission to revolutionize the treatment of urological disorders, primarily BPH. Its core achievement is the development of fexapotide triflutate, a novel injectable oligopeptide that has completed large Phase 3 trials and demonstrated durable symptom relief and a reduction in surgical interventions in long-term studies. The company's strategy is to advance this single asset through regulatory approval, leveraging a lean, virtual operational model to manage resources while targeting a massive, aging global population in need of better BPH therapies.

Therapeutic Areas

Other Benign Prostatic Hyperplasia (BPH) Drugs